🇺🇸 FDA
Patent

US 10105354

Inhibition of crystal growth of roflumilast

granted A61KA61K31/44A61K45/06

Quick answer

US patent 10105354 (Inhibition of crystal growth of roflumilast) held by Arcutis, Inc. expires Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arcutis, Inc.
Grant date
Tue Oct 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/44, A61K45/06, A61K47/10, A61K9/0014